Clinical trials: Cancer Disease Progression
Breast Cancer
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without…
- Trial name
- NCT01480674
- Testing
- Trastuzumab
- Where
- 78 sites in France
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma, First Relapse/Progression
Idiotypic Vaccination for Follicular Lymphoma Patients
Poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6 years. The proposed trial offers life-time idiotypic vaccination to all such patients in first relapse/progression who will achieve…
- Trial name
- FLIDVAX2006 (NCT00530140)
- Testing
- Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Nasopharyngeal Carcinoma
Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC
PET/CT and EBV DNA are important in diagnosis of NPC. We consider that combining post-treament PET/CT and plasma EBV DNA may be effective in evaluating the hazard of progression in the follow-up of Locally Advanced Nasopharyngeal…
- Trial name
- NCT03601390
- Testing
- PET/CT and EBV DNA
- Where
- China
- Volunteers
- 387 people
- Sponsor
- Sun Yat-sen University
Mesothelioma, Malignant
Niraparib Efficacy in Patient With Unresectable Mesothelioma
Multicentre, 2 arm, open-label UK randomised phase II trial to determine the efficacy of niraparib versus active symptom control (ASC) in patients who have relapsed after previously receiving platinum based systemic therapy.
- Trial name
- NERO (NCT05455424)
- Testing
- Niraparib Oral Product, Active Symptom Control
- Where
- 11 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Prostate Cancer Metastatic
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and…
- Trial name
- LUTRAC (NCT06260410)
- Testing
- Blood draw for ctDNA and circulating tumor cell collection.
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Erasmus Medical Center
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase II trial studies the side effects and best dose of total-body irradiation when given together with fludarabine phosphate followed by a donor peripheral stem cell transplant in treating patients with myelodysplastic…
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia
- Trial name
- NCT00397813
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes…
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1
- Trial name
- NCT03375320
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 432 sites in United States
- Volunteers
- 298 people
- Sponsor
- National Cancer Institute (NCI)
Myasthenia Gravis (MG), Myasthenia Gravis, Generalized
AXIS MG Patient Registry
The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis Crisis
- Trial name
- AXIS (NCT07761026)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Autoimmune Neurology Alliance
Hypoxia, Lactic Acidosis
The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression
The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses.
- Trial name
- NCT00638040
- Where
- United States
- Sponsor
- Duke University
Myasthenia Gravis
Clinical Prognosis and Progression of Myasthenia Gravis Patients
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.
- Trial name
- NCT04101578
- Testing
- Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Da, Yuwei, M.D.
Myeloid Malignancies, Lymphoid Malignancies
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
This is a randomized, parallel phase II study to evaluate the rates of progression-free survival and unacceptable toxicity in patients receiving NK cell-enriched donor lymphocyte infusions (DLIs) when administered alone or…
- Trial name
- NK-DCI (NCT02452697)
- Testing
- NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cristina Gasparetto
Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
It is still a challenge for urologic surgeon to prevent the post transurethral resection of bladder tumor (TURBT) recurrence of moderate-high risk non-muscle invasive bladder tumor.
- Conditions
- Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence
- Trial name
- NCT02716961
- Testing
- Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Barrett's Esophagus, Gastroesophageal Reflux Disease
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer.
- Conditions
- Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma
- Trial name
- NCT00574327
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Midwest Biomedical Research
Lymphoma, Large-Cell, Diffuse
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
- Trial name
- NCT00622388
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Glioma
Enzastaurin to Treat Recurrent Brain Tumor
This study will examine the safety of a twice-a-day dosing regimen of the experimental drug Enzastaurin in patients with malignant glioma (a cancerous brain tumor) who are and who are not taking certain anti-seizure medicines.
- Trial name
- NCT00108056
- Testing
- Enzastaurin (LY317615) monohydronchloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
This study aims at enrolling patients with solid tumors at metastatic stage, considered long responders to immunotherapy (> 6 months) and displaying disease progression.
- Trial name
- RESTO-IMMUNO (NCT06363773)
- Testing
- Stereotactic Radiotherapy
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Elsan
Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the performance of a CT/PET/ WSI-based deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy, Complete Pathological Response
- Trial name
- NCT05925751
- Testing
- CT/PET/WSI-based Deep Learning Signature
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
This is a retrospective observational, open label study to evaluate and prospectively validate in a blind manner the accuracy of predicting treatment outcomes by PrediCare in individual patients with Non-Small Cell Lung Cancer…
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Prostate Cancer, Breast Cancer
- Trial name
- NCT02577627
- Testing
- PrediCare
- Where
- Israel
- Volunteers
- 5,000 people
- Sponsor
- Optimata Ltd.
Bladder Cancer
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Green tea extract (Polyphenon® E) contains certain ingredients that may slow the growth of tumor cells and prevent the…
- Trial name
- NCT00088946
- Testing
- Polyphenon E, erlotinib hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.